Background Multi Drug Resistant Tuberculosis (MDR TB) is a threat to global tuberculosis control. A significant fitness cost has been associated with DR strains from specific lineages. Evaluation of the influence of the competing drug susceptible strains on fitness of drug resistant strains may have an important bearing on understanding the spread of MDR TB. The aim of this study was to evaluate the fitness of MDR TB strains, from a TB endemic region of western India: Mumbai, belonging to 3 predominant lineages namely CAS, Beijing and MANU in the presence of drug susceptible strains from the same lineages. Methodology Drug susceptible strains from a single lineage were mixed with drug resistant strain, bearing particular non synonymous mutation (rpoB D516V; inhA, A16G; katG, S315T1/T2) from the same or different lineages. Fitness of M.tuberculosis (M.tb) strains was evaluated using the difference in growth rates obtained by using the CFU assay system. Conclusion/Significance While MANU were most fit amongst the drug susceptible strains of the 3 lineages, only Beijing MDR strains were found to grow in the presence of any of the competing drug susceptible strains. A disproportionate increase in Beijing MDR could be an alarm for an impending epidemic in this locale. In addition to particular non synonymous substitutions, the competing strains in an environment may impact the fitness of circulating drug resistant strains.
References
[1]
Wagner A (2005) Robustness, evolvability, and neutrality. FEBS Letters 579: 1772–1778.
[2]
Dhar N, McKinney J-D (2007) Microbial phenotypic heterogeneity and antibiotic tolerance. Curr opin Microb 10: 30–38.
[3]
Normark B-H, Normark S (2002) Evolution and spread of antibiotic resistance. J Internal Med 252: 91–106.
[4]
Kremer K, van der Werf M-J, Au B-K-Y, Anh D-D, Kam K-M, et al. (2009) Vaccine-induced immunity circumvented by typical Mycobacterium tuberculosis Beijing strains. Emer Infect Dis 15(2): 335–339.
[5]
Hanekom M, Spuy van der G-D, Streicher E, Ndabambi S-L, McEvoy C-R-E, et al. (2007) A recently evolved sublineage of the Mycobacterium tuberculosis Beijing strain family is associated with an increased ability to spread and cause disease. J Clin Microbiol 45: 2263–2266.
[6]
Gagneux S, Long C-D, Small P, Van T, Schoolnik G-K, et al. (2006) The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 312: 1944–1946.
[7]
Strauss O-J, Warren R- M, Jordaan A, Streicher E-M, Hanekom M, et al. (2008) Spread of a low fitness drug resistant Mycobacterium tuberculosis strain in a setting of high Human Immunodeficiency Virus prevalence. J Clin Microb 46(4): 1514–1516.
[8]
Andersson DI, Levin BR (1999) The biological cost of antibiotic resistance. Curr Opin Microb 2(5): 489–493.
[9]
Groll A-V, Martin A, Stehr M, Singh M, Portaels F, et al. (2010) Fitness of Mycobacterium tuberculosis Strains of the W-Beijing and Non-W-Beijing genotype. PLoS One 5(4): e10191.
[10]
D'souza D, Mistry N-F, Vira T, Dholakia Y, Hoffner S-E, et al. (2009) High levels of Multidrug Resistant Tuberculosis in new and treatment-failure patients from the Revised National Tuberculosis Control Programme in an Urban metropolis (Mumbai) in Western India. BMC Public Health 9: 211.
[11]
Rodrigues C, Shenai S, Sadani M, Thakkar P, Sodha A, et al. (2006) Multi drug-resistant tuberculosis in Mumbai: it's only getting worse. Int J Tuberc Lung Dis 10: 1421–1422.
[12]
Chowgule R-V, Deodhar L (1998) Pattern of Secondary acquired drug resistance to antituberculosis drugs in Mumbai, India 1991–1995. Indian J Chest Dis Allied Sciences 40: 23–31.
[13]
Mistry N-F, Iyer A-M, D'souza D-T, Taylor G-M, Young D-B, et al. (2002) Spoligotyping of Mycobacterium tuberculosis isolates from multiple-drug-resistant tuberculosis patients from Bombay, India. J Clin Microb 40(7): 2677–2680.
[14]
Chatterjee A, D'Souza D, Vira T, Bamne A, Ambe G-T, et al. (2010) Strains of Mycobacterium tuberculosis from western Maharashtra, India, exhibit a high degree of diversity and strain-specific associations with drug resistance, cavitary disease, and treatment failure. J Clin Microb 10: 3593–3599.
[15]
Kulkarni S, Sola C, Filliol I, Rastogi N, Kadival G (2005) Spoligotyping of Mycobacterium tuberculosis isolates from patients with pulmonary tuberculosis in Mumbai, India. Research in Microbiology 156(4): 588–596.
[16]
Cohen T, Colijn C, Murray M (2008) Modeling the effects of strain diversity and mechanisms of strain competition on the potential performance of new tuberculosis vaccines. Proc Natl Acad Sci USA 105(42): 16302–16307.
[17]
Mariam HD, Mengistu Y, Hoffner SE, Andersson DI (2004) Effect of rpoB mutations conferring resistance on fitness of Mycobacterium tuberculosis. Antimicrob Agents Chemo 48(4): 1289–94.
[18]
Albert H, Bwanga F, Mukkada S, Nyesiga B, Ademun P-J, et al. (2010) Rapid screening of MDR-TB using molecular Line Probe Assay is feasible in Uganda. BMC infect Dis 10: 41.
[19]
Siddiqui N, Shamim M, Hussain S, Choudhary RK, Ahmed N, et al. (2002) Molecular characterization of Multi-Drug resistant isolates if Mycobacterium tuberculosis from patients in North India. AAC 46(2): 443–50.
[20]
Billington OJ, McHugh TD, Gillespie SH (1999) Physiological Cost of Rifampin Resistance Induced In Vitro in Mycobacterium tuberculosis. Antimicrob Agents Chemo 43(8): 1866–1869.
[21]
Be'er A, Zhang HP, Florin E-L, Payne S-M, Jacob EB (2008) Deadly competition between sibling bacterial colonies. Proc Natl Acad Sci USA 106(2): 428–433.
[22]
Sergeev R, Colijin C, Cohen T (2011) Models to understand the population level impact of mixed strain M.tuberculosis infections. J theoretical Biology 280: 88–100.
[23]
Tailleux L, Wadell SJ, Pelizzola M, Mortellaro A, Withers M, et al. (2008) Probing host pathogen cross talk by transcriptional profiling of both mycobacterium tuberculosis and infected human dendritic cells and Macrophages. PloS ONE 3(1): e1403.
[24]
Saito H, Tomioka H, Watanabe T, Yoneyama T (1983) Mycobacteriocins produced by mycobacteria are tween hydrolyzing esterases. J Bacteriol 153(3): 1294–1300.
